Prakiraan pendapatan perusahaan AON (AONC)

Simbol resmi perusahaan aoncology.com (AONC)

The investment potential of American Oncology Network (AONC) is based on its resilience to sanctions, although inflation is driving up equipment costs. The company's target sales dynamics on the GURU.Markets system chart confirm this, where the 1.02 indicator points to its development status. Stability is ensured by an ecosystem of clinics with in-house pharmacies, despite strict Medicare oversight and raw material shortage risks from Asia.

AONC - Volume dodolan sing dikarepake perusahaan aoncology.com ing rentang 21.02.2024 - 04.08.2024

Rincian analitis lan laporan data perusahaan American Oncology Network (AONC)

Analisis fundamental perusahaan:American Oncology Network Inc
Produk merek AON

This indicator serves as a key filter for asset stress testing and stock selection, measuring projected revenue to reflect business scalability and resilience to market shocks. The current value of 1.02 in assessing the company's future sales allows for the identification of hidden stagnation risks. For American Oncology Network (AONC), the trend of this metric is critical due to regulatory pressure on drug pricing. A decline in this metric could signal a drain of specialists and rising compliance costs.

Analisis perusahaan pesaing

Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan pendapatan perusahaan ymabs.com (YMAB)|Prakiraan pendapatan perusahaan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Volume dodolan mangsa ngarep perusahaan|Accuray Inc. (ARAY) - Volume dodolan sing dikarepake perusahaan|SELLAS Life Sciences Group, Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Prakiraan pendapatan perusahaan|HURA - Dodolan mangsa ngarep perusahaan|TARA (Protara Therapeutics, Inc.) - Prakiraan volume dodolan|Prakiraan volume dodolan Fate Therapeutics Inc|Prakiraan volume dodolan WHWK|Prakiraan volume dodolan TScan Therapeutics Inc (TCRX)|Prakiraan pendapatan perusahaan championsoncology.com CSBR|XBIT - Volume dodolan mangsa ngarep perusahaan|CVM - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan OSTX (OS Therapies)|RADX: Prakiraan volume dodolan|Artiva Biotherapeutics Inc. - Pendapatan mangsa ngarep perusahaan|ANL (Adlai Nortye) - Prakiraan volume dodolan|Prakiraan volume dodolan verupharma.com|Volume dodolan mangsa ngarep perusahaan TPST (tempesttx.com)|Volume dodolan mangsa ngarep perusahaan Xilio Therapeutics Inc XLO|Prakiraan volume dodolan RENB (Enochian BioSciences)|Mural Bio - Prakiraan pendapatan perusahaan|KAPA - Prakiraan pendapatan perusahaan|OnKure Therapeutics (OKUR) - Volume dodolan mangsa ngarep perusahaan|GDTC: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Tharimmune Corp (THAR)|Prakiraan volume dodolan ADVB|GNPX - Volume dodolan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan calidibio.com CLDI|SBFM - Volume dodolan mangsa ngarep perusahaan|XBIO - Prakiraan pendapatan perusahaan|SLRX: Prakiraan pendapatan perusahaan|Purple Biotech (PPBT) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan